 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...6789101112131415161718» |
- | Leukeran (chlorambucil) / GSK
Clinical, Journal: Blastoid variant of mantle cell lymphoma of the female urethra mimicking a caruncle: A rare but highly aggressive subtype case with literature review. (Pubmed Central) - Aug 3, 2019
She died of disseminated disease 6 months after diagnosis. A review of the lymphomas of the urethra is included.
- | Leukeran (chlorambucil) / GSK
Journal, Combination therapy: A Supramolecular Hydrogel Based on Chlorambucil and Peptide Drug for Cancer Combination Therapy. (Pubmed Central) - Aug 3, 2019
As a consequence, it exhibited enhanced antitumor efficiency both in vitro and in vivo with favorable biocompatibility. This biocompatible self-delivery drug system could not only significantly improve the delivery efficiency of the small molecule drugs but also adequately synergize the antitumor effect of CRB and YSV, inspiring the design of new strategies of cancer combination therapy.
- | cyclophosphamide intravenous / generics
Preclinical, Journal: Polyphenols enhance the activity of alkylating agents in leukaemia cell lines. (Pubmed Central) - Jul 31, 2019
The combination of alkylating agents, particularly cisplatin with polyphenols could be promising for the treatment of lymphoid leukaemias, with apigenin showing the greatest effects. Likewise in myeloid cells apigenin also synergised the action of all alkylating agents, suggesting that apigenin may also be beneficial in myeloid leukaemias.
- | Quinamed (amonafide) / Teva, Leukeran (chlorambucil) / GSK
Journal: Synthesis and biological studies of new multifunctional curcumin platforms for anticancer drug delivery. (Pubmed Central) - Jul 24, 2019
Likewise in myeloid cells apigenin also synergised the action of all alkylating agents, suggesting that apigenin may also be beneficial in myeloid leukaemias. The approach presented here may prove beneficial for bioactive curcumin-based delivery applications where multiple drug delivery is required in a consecutive and controlled mode.
- | Leukeran (chlorambucil) / GSK, ibrutinib / Generic mfg.
Clinical, P3 data, Journal: Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. (Pubmed Central) - Jul 21, 2019
The approach presented here may prove beneficial for bioactive curcumin-based delivery applications where multiple drug delivery is required in a consecutive and controlled mode. No abstract available
- | Rituxan (rituximab) / Roche, Biogen
Clinical, Journal: Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. (Pubmed Central) - Jul 17, 2019
P4
Overall adverse event incidence was similar (rituximab plus bendamustine, 98%; rituximab plus chlorambucil, 97%). Rituximab plus bendamustine may be a valuable first-line option for fludarabine-ineligible patients with chronic lymphocytic leukemia.
- | Rituxan (rituximab) / Roche, Biogen
Clinical, Journal: Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. (Pubmed Central) - Jul 17, 2019
The remaining patients received CLB (n = 19) or fludarabine (F, n = 10), F/cyclophosphamide (FC, n = 1), FC/rituximab (FCR, n = 2) or bendamustine/rituximab (BR, n = 3)...These findings suggest that anti-leukaemic treatment including chemoimmunotherapy is feasible and efficacious in ≥80-year-old CLL patients. However, this group of patients lives for a shorter time than age-matched controls of the general population.
- || Leukeran (chlorambucil) / GSK
Never ever use chlorambucil - vile drug. #modified #ponticelli #cyclophosphamide. Major limitation of the @RenalAssoc #membranous #trial (Twitter) - Jul 12, 2019
- || Leukeran (chlorambucil) / GSK
Agree Dr. Glassock. The difference in practice that has become evident is not b/w using Cyclophosphamide in place of Chlorambucil. The variation in practice appears to be in the dose, frequency, route (IV,PO) of steroids, duration & dose of Cyclophosphamide (Twitter) - Jul 12, 2019
- ||| Leukeran (chlorambucil) / GSK
Clinical: Of course, anytime you modify an established regimen upon which the evidence of efficacy is based, you can no longer use the evidence. I prefer to use the CYC-based Ponticelli regimen as it was originally designed and studied. I have not used Chlorambucil for “decades” . (Twitter) - Jul 12, 2019
- |||| Leukeran (chlorambucil) / GSK
Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy ca. 1984 from @NEJM #VisualAbstract by @CristhianMuM #Nephpearls #NephJC 👉🏼 https://t.co/KcY2ZcuLJK (Twitter) - Jul 9, 2019
- || Leukeran (chlorambucil) / GSK
your wish list? Nooooo! out for dinner out as kids away in @visit_donegal . anyway I know nada about GN, I just ask @mcq_emily or @geddescc (though why study against CycA when UK membranous favoured chlorambucil...). Nope I've not read MENTOR yet as just back from holiday (Twitter) - Jul 9, 2019
- ||||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: GLOW: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov) - Jun 28, 2019
P3, N=211, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
However, this group of patients lives for a shorter time than age-matched controls of the general population. Recruiting --> Active, not recruiting
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche, Rituxan (rituximab) / Roche, Biogen
Journal: Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy. (Pubmed Central) - Jun 26, 2019
In our patients obinutuzumab was effective as first-line treatment of anti-MAG antibody polyneuropathy. CLL might have had a role in the response to therapy, but the associations might be considered in future trials.
- ||||||||| Arzerra (ofatumumab) / Novartis, Genmab
Trial termination, Monotherapy: COMPLEMENT 1: Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jun 25, 2019
P3, N=447, Terminated, Sponsor: Novartis Pharmaceuticals
CLL might have had a role in the response to therapy, but the associations might be considered in future trials. Completed --> Terminated; Majority of patients (62%) had been treated with next line therapies, including new highly effective therapies confounding the interpretation of the OS results.
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal, IO biomarker: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. (Pubmed Central) - Jun 22, 2019
P3
Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.).
- |||| Leukeran (chlorambucil) / GSK
Clinical: The best of the best session in #15ICML Congratulation @VincentRK The case of Insulin in USA is scary. It reminded me about melphalan, chlorambucil, asparaginase and more recently bleomycin in Brazil. 👏👏👏👏 (Twitter) - Jun 21, 2019
- ||| Leukeran (chlorambucil) / GSK
Clinical: I guess hard to justify ibrut (a la illuminate) given cardiac risk in good risk pts, especially elderly. When will Chlorambucil ever die lol (Twitter) - Jun 20, 2019
- | Leukeran (chlorambucil) / GSK
Journal: Combination treatment of p53-null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression. (Pubmed Central) - Jun 19, 2019
The combination treatment of p53-null HL-60 cells with DNA-damaging agent CLB and HDACIs NaBu and TSA triggered additive to synergistic effects on apoptosis and upregulated BCL6 and p21 expression. These findings reveal BCL6 and p21 as potential targets of chemo-resistance for the development of anti-leukaemic drugs.
- | Leukeran (chlorambucil) / GSK
Preclinical, Journal: In vitro activity of resorcinarene-chlorambucil conjugates for therapy in human chronic myelogenous leukemia cells. (Pubmed Central) - Jun 17, 2019
Thus, four resorcinarene-PAMAM-dendrimer conjugates of chlorambucil with different groups in the lower part of the macrocycle and different length dendritic arms showed a good stability of the chemical link between drug and spacer. Evaluation of the cytotoxicity of the resorcinarene-PAMAM-dendrimer-chlorambucil conjugate employing a sulforhodamine B (SRB) assay in K-562 (human chronic myelogenous leukemia cells) demonstrated that the conjugate was more potent as an antiproliferative agent than chlorambucil.
- | Leukeran (chlorambucil) / GSK
Journal: A statistical approach for analyzing data from the in vivo Pig-a gene mutation assay. (Pubmed Central) - Jun 15, 2019
In doing so, multiple contrast tests allow us to discover time-related changes within and between treatment groups in addition to multiple treatment comparisons to a control group per single time point. We compare our proposed strategy with the results of classical Dunnett and Wilcoxon-Mann-Whitney tests using two data sets describing the mode of action of Chlorambucil and Glycidyl methacrylate both analyzed in a 28-day treatment schedule.
- | Rituxan (rituximab) / Roche, Biogen
Retrospective data, Journal: Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials. (Pubmed Central) - Jun 9, 2019
Our results suggest that cyclophosphamide may be preferred initially in children with FRSN/SDNS, chlorambucil, and rituximab may be acceptable medications for patients with FRSN/SDNS. Long-term follow-up trials focused on gonadal toxicity and limitation of maximum dosage of cyclophosphamide should been carried out.
- || Leukeran (chlorambucil) / GSK
Reminds me of our NEJM letter on chlorambucil. (Twitter) - Jun 7, 2019
- ||| Leukeran (chlorambucil) / GSK
Clinical: From what I gather from @VPrasadMDMPH , he hates chlorambucil when used as a comparator in drug trials where it's long since ceased to be used in clinical practice. (Twitter) - Jun 6, 2019
- ||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
Clinical: Hate chlorambucil as much as you want - hard to argue it hasn't been an acceptable standard in older patients who cannot tolerate BR/FCR. Combo therapy with obinutuzumab preserved it for a while, but I think it will soon cease to function as a comparitor arm following 2019/20 (Twitter) - Jun 6, 2019
- ||| Leukeran (chlorambucil) / GSK
Clinical, FDA event: As suspected . No us patients on study because no one here is comfortable using chlorambucil as front line . Yet fda will approve it here (Twitter) - Jun 6, 2019
- ||| Leukeran (chlorambucil) / GSK
Clinical, Monotherapy: An unnamed prior co-fellow of mine referred to chlorambucil as a “toxic placebo” which I like .. not clear if the chlor is really adding much and I’ll also occasionally use obi monotherapy for untreated pts (Byrd et al Blood 2016) (Twitter) - Jun 5, 2019
- || Leukeran (chlorambucil) / GSK
I think Chlorambucil-G is obsolete (and maybe has been for a few years). @calliecoombsmd @Maryam_Yazdy (Twitter) - Jun 5, 2019
- ||||| Venclexta (venetoclax) / Roche, AbbVie, Leukeran (chlorambucil) / GSK
Clinical: Groundbreaking study in 1L CLL patients with co-morbidities: Obinu + chlorambucil vs Obinu + Venetoclax (CLL14); fixed duration treatment of 1 year. Approx 90% EFS at 2 yrs. Approx 90% PFS at 2 yrs even in unmut IgVH and 70% 2 yr PFS in p53 del/mut https://t.co/WETQIAP4F7 (Twitter) - Jun 5, 2019
- || Venclexta (venetoclax) / Roche, AbbVie, Leukeran (chlorambucil) / GSK, Imbruvica (ibrutinib) / AbbVie, J&J
another “reasonable” front-line regimen. This or Ibrutinib alone, ibr-R, venetoclax-R, or ven alone? Is Chlorambucil-G obsolete? @DrRaulCordoba @tobyeyre82 @HallekMichael @graham74GC @anthonymatomd @DrMatasar @JohnPLeonardMD @SoniSmithMD @jeff_sharman https://t.co/VyVm9EHRi2 (Twitter) - Jun 4, 2019
- || Leukeran (chlorambucil) / GSK
What if it's chlorambucil? (Twitter) - May 30, 2019
- | Leukeran (chlorambucil) / GSK
Journal: Low-grade gastrointestinal lymphoma in dogs: 20 cases (2010 to 2016). (Pubmed Central) - May 30, 2019
Low-grade gastrointestinal lymphoma appears to be a rare condition in dogs, and treatment with chemotherapy results in a high response rate and favourable survival times. Further study is needed to determine its prevalence in dogs with chronic enteropathies.
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
Journal: Frontline treatment of chronic lymphocytic leukemia with obinutuzumab and chlorambucil: how does it work in "real‑life"? (Pubmed Central) - May 29, 2019
Further study is needed to determine its prevalence in dogs with chronic enteropathies. No abstract available
- | Leukeran (chlorambucil) / GSK
Journal, BRCA Biomarker, PARP Biomarker: Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. (Pubmed Central) - May 28, 2019
Importantly, chlorambucil is substantially less toxic to normal cells and tissues in vitro and in vivo relative to cisplatin. Because chlorambucil and cisplatin are equally effective inhibitors of BRCA2-compromised tumours, our results indicate that chlorambucil has a higher therapeutic index than cisplatin in targeting BRCA-deficient tumours.
- |||| Leukeran (chlorambucil) / GSK, Imbruvica (ibrutinib) / AbbVie, J&J
Clinical: Yes, a few years ago I went to treat a 90+ y/o with cll and found that with copay assist, ibrutinib was much less direct patient cost than chlorambucil by few hundred dollars per month (Twitter) - May 25, 2019
- ||| Leukeran (chlorambucil) / GSK
You don’t really have to wait too long: these are the pharmacies with the cheapest cash prices for chlorambucil this morning (for 15 pills) (Twitter) - May 25, 2019
- |||| Leukeran (chlorambucil) / GSK
Clinical: I am rebranding chlorambucil, as the drug price is already hard enough. I wonder if this would work for maintenance therapy in pancreatic cancer to prevent resistance. (Twitter) - May 25, 2019
- || Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
@EmboMolMed @IREISGufficiale @The_OIRO didn’t they jack up the price when gazyva chlorambucil data came out? (Twitter) - May 24, 2019
- || Leukeran (chlorambucil) / GSK
Interesting ... pretty soon chlorambucil will be $500 per pill.....HT @ESchattner (Twitter) - May 24, 2019
- |||| Leukeran (chlorambucil) / GSK
Preclinical: Interesting preclinical study of chlorambucil sensitivity in BRCA deficient cancers. Cc: @MPishvaian (Twitter) - May 24, 2019
- || Leukeran (chlorambucil) / GSK
My filter is, would I want my relatives or friends in these trials? Chlorambucil as control arm when it's been abandoned for 10 years? That's not a hard question. Others are much harder. 🤷♀️ (Twitter) - May 23, 2019
- || Leukeran (chlorambucil) / GSK
This is a frequent criticism of his: trials that use a control arm below SOC, e.g., a long-abandoned treatment, almost infamously by now in many of his examples chlorambucil. Is he wrong here about the control arm? (Twitter) - May 23, 2019
- ||| Leukeran (chlorambucil) / GSK
Chlorambucil is the Washington Generals of chemotherapy. It’s amazing how many times I get to keep using this joke. (Twitter) - May 16, 2019
- ||| Leukeran (chlorambucil) / GSK
Monotherapy: point taken; yet obi chlorambucil is "SOC" by virtue of beating.... monotherapy chlorambucil! at a time when that was not SOC. Its a daisy chain rooted in inadequate comparators. (Twitter) - May 16, 2019
- ||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Clinical, P3 data, Monotherapy: At least in this case the control wasn’t chlorambucil monotherapy; that would have been unconscionable at trial start in ~2014. Similar design to the ILLUMINATE Phase 3 (ibrutinib + obinutuzumab vs chlorambucil + obinutuzumab) - that one reported out a few months ago. (Twitter) - May 16, 2019
- || Leukeran (chlorambucil) / GSK
¿Ya intentaron hablar directamente al fabricante GlaxoSmithKline de México? Calzada México-Xochimilco N° 4900 Col. San Lorenzo Huipulco C.P. 14370 México, D.F. Teléfono: 5483 8300 // @gsk Here you have a customer trying to get Chlorambucil in Mexico unsuccessfully. (Twitter) - May 12, 2019
- | Leukeran (chlorambucil) / GSK
Journal: Catalytic asymmetric acetalization of carboxylic acids for access to chiral phthalidyl ester prodrugs. (Pubmed Central) - May 9, 2019
Preliminary bioactivity studies show that the two enantiomers of chlorambucil phthalidyl esters exhibit different anti-cancer activities to inhibit the growth of Hela cells. Our catalytic strategy of asymmetric acetalizations of carboxylic acids shall benefit future development of chiral phthalidyl ester prodrugs and related molecules.
- |||| Leukeran (chlorambucil) / GSK
Clinical, Review: One way to make a randomized trial more likely to be 'positive' is to use a crummy "straw man" control arm - remember all those "new drug vs chlorambucil" (not SOC for >10 years) trials in #CLL.New systematic review by @TalalHilal @vprasadmdmph in @JAMAOnc https://t.co/mgMSWE84Po (Twitter) - May 3, 2019
- | Leukeran (chlorambucil) / GSK
Journal: Behind the Mirror: Chirality Tunes the Reactivity and Cytotoxicity of Chloropiperidines as Potential Anticancer Agents. (Pubmed Central) - Apr 19, 2019
Very interestingly, stereochemistry modulated the activity of M-CePs in unexpected ways, pointing to additional molecular mechanisms of action beyond the direct damage of genomic DNA. This encouraging combination of efficacy and sustainability suggests they are valid candidates for anticancer agent development.
- | Imbruvica (ibrutinib) / AbbVie, J&J
Clinical, Journal, HEOR: Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. (Pubmed Central) - Apr 5, 2019
When the comparator efficacy is increased to more closely match that seen in trials evaluating chemoimmunotherapy, ibrutinib costs more than $262 000 per QALY gained, and the monthly cost of ibrutinib would need to be lowered to less than $5000 per month to be cost-effective. Ibrutinib is not cost-effective as initial therapy at a WTP threshold of $150 000 per QALY gained.